1
|
Li W, Wang M, Meng B, Yu J, Chen Q, Li H, Liu Y. MicroRNA-153 regulated AKT1 expression and suppressed cell proliferation of epithelial ovarian cancer cells. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2017; 10:7417-7426. [PMID: 31966584 PMCID: PMC6965221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 09/04/2016] [Accepted: 03/17/2017] [Indexed: 06/10/2023]
Abstract
Epithelial ovarian cancer (EOC) is the most fatal malignancies in females worldwide, with increasing incidence recently in China. MiR-153 was reported to be dysregulated in some human cancers, including EOC. In this study, we explored the roles of miR-153 and its target AKT1 in regulating growth and migration in EOC. Cell proliferation was measured with a CCK-8 assay. Real-time quantitative RT-PCR was performed to investigate expression levels of miR-153. Cell cycle features were analyzed by Flow cytometry system. The direct target gene was confirmed by dual-luciferase reporter assay. We found the expression levels of miR-153 were generally lower in the EOC tissues than in the matched normal tissues. The miR-153 mimics caused significant G0/G1 arrest in A2780 cells. Overexpression of miR-153 suppressed cell proliferation and migration in ovarian cancer. Results of dual-luciferase reporter assay suggested that AKT1 was a direct target of miR-153 in ovarian cancer cells. Overexpression of AKT1 reverses the inhibition effect of miR-153 on cell proliferation. Introduction of miR-153 into EOC cell lines leaded to inhibition of cell proliferation and migration by directly targeting AKT1. MiR-153 may have prognostic or therapeutic value for the future management of ovarian cancer patients.
Collapse
Affiliation(s)
- Weizhen Li
- Department of Clinical Laboratory, The Taixing People’s HospitalTaixing, Jiangsu, China
| | - Mengjie Wang
- Bengbu Medical SchoolBengbu, Anhui, China
- Department of Radiotherapy, The Taixing People’s HospitalTaixing, Jiangsu, China
| | - Bi Meng
- Bengbu Medical SchoolBengbu, Anhui, China
- Department of Radiotherapy, The Taixing People’s HospitalTaixing, Jiangsu, China
| | - Jingwen Yu
- Bengbu Medical SchoolBengbu, Anhui, China
- Department of Obstetrics and Gynecology, The Taixing People’s HospitalTaixing, Jiangsu, China
| | - Qiaoyun Chen
- Department of Central Laboratory, The Affiliated People’s Hospital of Jiangsu UniversityZhenjiang, Jiangsu, China
| | - Hao Li
- Department of Clinical Laboratory, The Taixing People’s HospitalTaixing, Jiangsu, China
| | - Yangchen Liu
- Department of Radiotherapy, The Taixing People’s HospitalTaixing, Jiangsu, China
| |
Collapse
|
2
|
ZOU YANG, DENG WEI, WANG FENG, YU XIAOHONG, LIU FAYING, YANG BICHENG, HUANG MEIZHEN, GUO JIUBAI, XIE QIUHUA, HE MING, HUANG OUPING. A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors. Oncol Rep 2015; 35:725-30. [DOI: 10.3892/or.2015.4402] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2015] [Accepted: 09/08/2015] [Indexed: 11/06/2022] Open
|
3
|
Shao X, He Y, Ji M, Chen X, Qi J, Shi W, Hao T, Ju S. Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett 2015; 10:3478-3482. [PMID: 26788153 PMCID: PMC4665352 DOI: 10.3892/ol.2015.3771] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 08/17/2015] [Indexed: 12/23/2022] Open
Abstract
The aim of the present study was to investigate the association between cell-free DNA (cf-DNA) levels and clinicopathological characteristics of patients with ovarian cancer using a branched DNA (bDNA) technique, and to determine the value of quantitative cf-DNA detection in assisting with the diagnosis of ovarian cancer. Serum specimens were collected from 36 patients with ovarian cancer on days 1, 3 and 7 following surgery, and additional serum samples were also collected from 22 benign ovarian tumor cases, and 19 healthy, non-cancerous ovaries. bDNA techniques were used to detect serum cf-DNA concentrations. All data were analyzed using SPSS version 18.0. The cf-DNA levels were significantly increased in the ovarian cancer group compared with those of the benign ovarian tumor group and healthy ovarian group (P<0.01). Furthermore, cf-DNA levels were significantly increased in stage III and IV ovarian cancer compared with those of stages I and II (P<0.01). In addition, cf-DNA levels were significantly increased on the first day post-surgery (P<0.01), and subsequently demonstrated a gradual decrease. In the ovarian cancer group, the area under the receiver operating characteristic curve of cf-DNA and the sensitivity were 0.917 and 88.9%, respectively, which was higher than those of cancer antigen 125 (0.724, 75%) and human epididymis protein 4 (0.743, 80.6%). There was a correlation between the levels of serum cf-DNA and the occurrence and development of ovarian cancer in the patients evaluated. bDNA techniques possessed higher sensitivity and specificity than other methods for the detection of serum cf-DNA in patients exhibiting ovarian cancer, and bDNA techniques are more useful for detecting cf-DNA than other factors. Thus, the present study demonstrated the potential value for the use of bDNA as an adjuvant diagnostic method for ovarian cancer.
Collapse
Affiliation(s)
- Xuefeng Shao
- Department of Clinical Laboratory, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China
| | - Yan He
- Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China
| | - Min Ji
- Department of Internal Medicine, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China
| | - Xiaofang Chen
- Department of Gynecology, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China
| | - Jing Qi
- Department of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China
| | - Wei Shi
- Department of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China
| | - Tianbo Hao
- Department of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China
| | - Shaoqing Ju
- Department of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China
| |
Collapse
|
4
|
Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 2014; 10:123-30. [PMID: 24379986 PMCID: PMC3860338 DOI: 10.7497/j.issn.2095-3941.2013.03.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 08/07/2013] [Indexed: 12/15/2022] Open
Abstract
Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.
Collapse
Affiliation(s)
- Hong Zheng
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
| | - Jia-Yu Liu
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
| | - Feng-Ju Song
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
| | - Ke-Xin Chen
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
| |
Collapse
|
5
|
Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2013; 32:48. [PMID: 23902592 PMCID: PMC3734167 DOI: 10.1186/1756-9966-32-48] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Accepted: 07/29/2013] [Indexed: 12/14/2022]
Abstract
In 2013 there will be an estimated 22,240 new diagnoses and 14,030 deaths from ovarian cancer in the United States. Despite the improved surgical approach and the novel active drugs that are available today in clinical practice, about 80% of women presenting with late-stage disease have a 5-year survival rate of only 30%. In the last years a growing scientific knowledge about the molecular pathways involved in ovarian carcinogenesis has led to the discovery and evaluation of several novel molecular targeted agents, with the aim to test alternative models of treatment in order to overcome the clinical problem of resistance. Cancer stem cells tend to be more resistant to chemotherapeutic agents and radiation than more differentiated cellular subtypes from the same tissue. In this context the study of ovarian cancer stem cells is taking on an increasingly important strategic role, mostly for the potential therapeutic application in the next future. In our review, we focused our attention on the molecular characteristics of epithelial ovarian cancer stem cells, in particular on possible targets to hit with targeted therapies.
Collapse
Affiliation(s)
- Federica Tomao
- Department of Gynaecology and Obstetrics, University of Rome, Sapienza, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
6
|
Wintzell M, Löfstedt L, Johansson J, Pedersen AB, Fuxe J, Shoshan M. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther 2012; 13:1454-62. [PMID: 22954696 DOI: 10.4161/cbt.22007] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Cisplatin is used in treatment of several types of cancer, including epithelial ovarian carcinoma (EOC). In order to mimic clinical treatment and to investigate longterm effects of cisplatin in surviving cancer cells, two EOC cell lines were repeatedly treated with low doses. In the SKOV-3 cell line originating from malignant ascites, but not in A2780 cells from a primary tumor, this led to emergence of a stable population (SKOV-3-R) which in the absence of cisplatin showed increased motility, epithelial-mesenchymal transition (EMT) and expression of cancer stem cell markers CD117, CD44 and ALDH1. Accordingly, the cells formed self-renewing spheres in serum-free stem cell medium. Despite upregulation of mitochondrial mass and cytochrome c, and no upregulation of Bcl-2/Bcl-xL, SKOV-3-R were multiresistant to antineoplastic drugs. Cancer stem cells, or tumor-initiating cells (TICs) are highly chemoresistant and are believed to cause relapse into disseminated and resistant EOC. Our second aim was therefore to target resistance in these TIC-like cells. Resistance could be correlated with upregulation of hexokinase-II and VDAC, which are known to form a survival-promoting mitochondrial complex. The cells were thus sensitive to 3-bromopyruvate, which dissociates hexokinase-II from this complex, and were particularly sensitive to combination treatment with cisplatin at doses down to 0.1 x IC 50. 3-bromopyruvate might thus be of use in targeting the especially aggressive TIC populations.
Collapse
Affiliation(s)
- My Wintzell
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|
7
|
Karve TM, Preet A, Sneed R, Salamanca C, Li X, Xu J, Kumar D, Rosen EM, Saha T. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells. PLoS One 2012; 7:e37697. [PMID: 22685544 PMCID: PMC3365892 DOI: 10.1371/journal.pone.0037697] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 04/26/2012] [Indexed: 11/19/2022] Open
Abstract
Follistatin (FST), a folliculogenesis regulating protein, is found in relatively high concentrations in female ovarian tissues. FST acts as an antagonist to Activin, which is often elevated in human ovarian carcinoma, and thus may serve as a potential target for therapeutic intervention against ovarian cancer. The breast cancer susceptibility gene 1 (BRCA1) is a known tumor suppressor gene in human breast cancer; however its role in ovarian cancer is not well understood. We performed microarray analysis on human ovarian carcinoma cell line SKOV3 that stably overexpress wild-type BRCA1 and compared with the corresponding empty vector-transfected clones. We found that stable expression of BRCA1 not only stimulates FST secretion but also simultaneously inhibits Activin expression. To determine the physiological importance of this phenomenon, we further investigated the effect of cellular BRCA1 on the FST secretion in immortalized ovarian surface epithelial (IOSE) cells derived from either normal human ovaries or ovaries of an ovarian cancer patient carrying a mutation in BRCA1 gene. Knock-down of BRCA1 in normal IOSE cells demonstrates down-regulation of FST secretion along with the simultaneous up-regulation of Activin expression. Furthermore, knock-down of FST in IOSE cell lines as well as SKOV3 cell line showed significantly reduced cell proliferation and decreased cell migration when compared with the respective controls. Thus, these findings suggest a novel function for BRCA1 as a regulator of FST expression and function in human ovarian cells.
Collapse
Affiliation(s)
- Tejaswita M. Karve
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., United States of America
- Department of Biochemistry and Cellular and Molecular Biology, Georgetown University School of Medicine, Washington, D.C., United States of America
| | - Anju Preet
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., United States of America
| | - Rosie Sneed
- University of District of Columbia, Washington, D.C., United States of America
| | - Clara Salamanca
- Canadian Ovarian Tissue Bank, BC Cancer Research Centre, Vancouver, B.C., Canada
| | - Xin Li
- Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University School of Medicine, Washington, D.C., United States of America
| | - Jingwen Xu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., United States of America
| | - Deepak Kumar
- University of District of Columbia, Washington, D.C., United States of America
| | - Eliot M. Rosen
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., United States of America
| | - Tapas Saha
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., United States of America
- * E-mail: (TS)
| |
Collapse
|
8
|
Mishur RJ, Rea SL. Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. MASS SPECTROMETRY REVIEWS 2012; 31:70-95. [PMID: 21538458 DOI: 10.1002/mas.20338] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2011] [Revised: 03/29/2011] [Accepted: 03/29/2011] [Indexed: 05/20/2023]
Abstract
Every 5 years or so new technologies, or new combinations of old ones, seemingly burst onto the science scene and are then sought after until they reach the point of becoming commonplace. Advances in mass spectrometry instrumentation, coupled with the establishment of standardized chemical fragmentation libraries, increased computing power, novel data-analysis algorithms, new scientific applications, and commercial prospects have made mass spectrometry-based metabolomics the latest sought-after technology. This methodology affords the ability to dynamically catalogue and quantify, in parallel, femtomole quantities of cellular metabolites. The study of aging, and the diseases that accompany it, has accelerated significantly in the last decade. Mutant genes that alter the rate of aging have been found that increase lifespan by up to 10-fold in some model organisms, and substantial progress has been made in understanding fundamental alterations that occur at both the mRNA and protein level in tissues of aging organisms. The application of metabolomics to aging research is still relatively new, but has already added significant insight into the aging process. In this review we summarize these findings. We have targeted our manuscript to two audiences: mass spectrometrists interested in applying their technical knowledge to unanswered questions in the aging field, and gerontologists interested in expanding their knowledge of both mass spectrometry and the most recent advances in aging-related metabolomics.
Collapse
Affiliation(s)
- Robert J Mishur
- Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245, USA.
| | | |
Collapse
|
9
|
Batra J, Nagle CM, O'Mara T, Higgins M, Dong Y, Tan OL, Lose F, Skeie LM, Srinivasan S, Bolton KL, Song H, Ramus SJ, Gayther SA, Pharoah PDP, Kedda MA, Spurdle AB, Clements JA. A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer 2011; 11:119. [PMID: 21457553 PMCID: PMC3080344 DOI: 10.1186/1471-2407-11-119] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 04/01/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival and overall survival in ovarian cancer. Our aim was to analyse the KLK15 gene for putative functional single nucleotide polymorphisms (SNPs) and assess the association of these and KLK15 HapMap tag SNPs with ovarian cancer survival. RESULTS In silico analysis was performed to identify KLK15 regulatory elements and to classify potentially functional SNPs in these regions. After SNP validation and identification by DNA sequencing of ovarian cancer cell lines and aggressive ovarian cancer patients, 9 SNPs were shortlisted and genotyped using the Sequenom iPLEX Mass Array platform in a cohort of Australian ovarian cancer patients (N = 319). In the Australian dataset we observed significantly worse survival for the KLK15 rs266851 SNP in a dominant model (Hazard Ratio (HR) 1.42, 95% CI 1.02-1.96). This association was observed in the same direction in two independent datasets, with a combined HR for the three studies of 1.16 (1.00-1.34). This SNP lies 15 bp downstream of a novel exon and is predicted to be involved in mRNA splicing. The mutant allele is also predicted to abrogate an HSF-2 binding site. CONCLUSIONS We provide evidence of association for the SNP rs266851 with ovarian cancer survival. Our results provide the impetus for downstream functional assays and additional independent validation studies to assess the role of KLK15 regulatory SNPs and KLK15 isoforms with alternative intracellular functional roles in ovarian cancer survival.
Collapse
Affiliation(s)
- Jyotsna Batra
- Australian Prostate Cancer Research centre-Queensland and Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Queensland 4059, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Pérez-López FR, Chedraui P, Troyano-Luque JM. Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. Gynecol Endocrinol 2010; 26:631-43. [PMID: 20500106 DOI: 10.3109/09513590.2010.487611] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Adnexal masses are common among peri- and post-menopausal women. Although ovarian cancer is a significant cause of mortality in menopausal women, large population-based studies demonstrate that the majority of adnexal masses are benign. Despite this, the appearance of an adnexal mass is a concern for the patient and an insight exercise for physicians. In most cases, an adnexal enlargement is an incidental finding, generally corresponding to a benign cyst and easily diagnosed by conventional ultrasound. Exceptionally an ovarian tumour may be malignant and should be treated as early as possible. When conventional ultrasound renders complex morphology other diagnostic tools must be used such as: colour Doppler and functional tumour vessel properties, serum CA 125 levels, nuclear magnetic resonance imaging and in some cases laparoscopy. Several new tumour markers are being studied for clinical application, although there are presently no clear recommendations. Adnexal masses with benign morphological and functional properties must be periodically monitored as an alternative to surgery since malignant transformation is exceptional.
Collapse
Affiliation(s)
- Faustino R Pérez-López
- Department of Obstetrics and Gynaecology, Facultad de Medicina, Universidad de Zaragoza, Hospital Clínico de Zaragoza, Zaragoza 50009, Spain.
| | | | | |
Collapse
|
11
|
Häusler SFM, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010; 103:693-700. [PMID: 20683447 PMCID: PMC2938264 DOI: 10.1038/sj.bjc.6605833] [Citation(s) in RCA: 156] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 06/28/2010] [Accepted: 07/07/2010] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Screening is an unsolved problem for ovarian cancer (OvCA). As late detection is equivalent to poor prognosis, we analysed whether OvCA patients show diagnostically meaningful microRNA (miRNA) patterns in blood cells. METHODS Blood-borne whole miRNome profiles from 24 patients with OvCA and 15 age- and sex-matched healthy controls were biostatistically evaluated. RESULTS Student's t-test revealed 147 significantly deregulated miRNAs before and 4 after Benjamini-Hochberg adjustment. Although these included miRNAs already linked to OvCA (e.g., miR-16, miR-155), others had never before been connected to specific diseases. A bioinformatically calculated miRNA profile allowed for discrimination between blood samples of OvCA patients and healthy controls with an accuracy of >76%. When only cancers of the serous subtype were considered and compared with an extended control group (n=39), accuracy, specificity and sensitivity all increased to >85%. CONCLUSION Our proof-of-principle study strengthens the hypothesis that neoplastic diseases generate characteristic miRNA fingerprints in blood cells. Still, the obtained OvCA-associated miRNA pattern is not yet sensitive and specific enough to permit the monitoring of disease progression or even preventive screening. Microarray-based miRNA profiling from peripheral blood could thus be combined with other markers to improve the notoriously difficult but important screening for OvCA.
Collapse
Affiliation(s)
- S F M Häusler
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - A Keller
- Febit Biomed Gmbh,Im Neuenheimer Feld 519, Heidelberg 69120, Germany
- Biomarker Discovery Center Heidelberg, Heidelberg 69120, Germany
| | - P A Chandran
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
- Graduate School for Life Sciences, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - K Ziegler
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - K Zipp
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - S Heuer
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - M Krockenberger
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - J B Engel
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - A Hönig
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - M Scheffler
- Febit Biomed Gmbh,Im Neuenheimer Feld 519, Heidelberg 69120, Germany
| | - J Dietl
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| | - J Wischhusen
- Department of Obstetrics and Gynaecology, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
- Interdisciplinary Center for Clinical Research, University of Würzburg, School of Medicine, Josef-Schneider-Strasse 4, Würzburg 97080, Germany
| |
Collapse
|
12
|
Abstract
In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.
Collapse
|
13
|
Simionato AVC, Carrilho E, Maggi Tavares MF. CE-MS and related techniques as a valuable tool in tumor biomarkers research. Electrophoresis 2010; 31:1214-1226. [DOI: 10.1002/elps.200900671] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|